Lung Cancer

NCCN updated its small-cell lung cancer guidelines, introducing lurbinectedin for maintenance therapy and removing the chemotherapy-free interval for better treatment strategies.

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

Promising phase 2 results for taletrectinib in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.

When combined with an anti–PD-L1 therapy, tarlatamab significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

The treatment was generally well-tolerated in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC).

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

Compared with docetaxel, adagrasib shows significant progression-free survival (PFS) benefits in patients with non–small cell lung cancer (NSCLC).

Zongertinib promises significant advancements in patient care.

The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer (NSCLC) and other diseases.

The action is significant for patients with extensive-stage small cell lung cancer (SCLC), a population with limited treatment options.

Both preclinical and translational evidence support MET inhibition as a therapeutic approach in patients with small cell lung cancer (SCLC).

New research links high perilipin 2 expression in lung adenocarcinoma to aggressive disease progression and shorter survival, highlighting potential treatment targets.

Amy C. Nieto delves into the latest advancements in non-small cell lung cancer (NSCLC) treatment, including sunvozertinib, a newly-approved therapy for challenging EGFR exon 20 insertion mutations.

The action is supported by positive safety and efficacy findings from the phase 1a/1b first-in-human Beamion LUNG-1 trial.

Recent data link a higher consumption of ultraprocessed food to increased lung cancer risk, highlighting the need for dietary changes and further research.

The combination regimen had stronger benefits in patients with locally advanced or metastatic epidermal growth receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC) than osimertinib alone.

Neladalkib enters phase 3 trials, targeting advanced ALK-positive NSCLC, promising improved outcomes for TKI-naive patients with brain metastases.

Nikita Dahake, MD; Hossein Borghaei, DO, MS; and Yasmine Baca, MS, PhD candidate, MB(ASCP)CM, explore how distinct HER2-alteration subtypes in non-small cell lung cancer (NSCLC) impact survival outcomes, co-mutation profiles, and treatment response to immunotherapy-based regimens.

Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.

Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.

At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.